Literature DB >> 23009720

Alarin 6-25Cys antagonizes alarin-specific effects on food intake and luteinizing hormone secretion.

Gregory S Fraley1, Emily Leathley, Alexis Nickols, Elizabeth Gerometta, Erika Coombs, Sarah Colton, Sara Gallemore, Abigail Lindberg, Barbara Kofler.   

Abstract

Previous data from our labs and from others have demonstrated that intracerebroventricular (ICV) injection of alarin has orexigenic activity and significantly increases plasma luteinizing hormone (LH) secretion in a gonadotropin-releasing hormone (GnRH) dependent manner. The purpose of the current experiments was to determine if the amino acids at the amino-terminal end of the alarin peptide are critical for alarin's effects on reproductive and feeding systems. First, we injected male mice ICV with full-length alarin (Ala1-25) or peptide fragments missing residues at the amino-terminal end (Ala3-25 or Ala6-25 Cys). Neither peptide fragment alone, significantly increased food intake in male mice compared to controls. Second, ICV injection of Ala1-25, but not Ala3-25, significantly (p < 0.01) increased GnRH-mediated LH secretion. Surprisingly, Ala6-25 Cys significantly (p < 0.05) inhibited plasma LH secretion and inhibited Ala1-25 actions. In conclusion, elimination of the first five amino acids of alarin not only abolishes the biological activity of alarin, but becomes an antagonist to alarin-specific effects. Furthermore, Ala6-25 Cys seems to act as a specific antagonist to putative alarin receptors and therefore may be an important tool in identifying alarin-specific receptors.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009720     DOI: 10.1016/j.npep.2012.08.007

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  7 in total

1.  ASSESSMENT OF SERUM ALARIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

Authors:  F Kilinc; F Demircan; N Gozel; E Onalan; A Karatas; Z Pekkolay; F A Özdemir
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

Review 2.  The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications.

Authors:  Endeshaw Chekol Abebe; Misganaw Asmamaw Mengstie; Mohammed Abdu Seid; Tabarak Malik; Tadesse Asmamaw Dejenie
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

3.  Expression of alarin in ependymoma and choroid plexus tumors.

Authors:  Nicole Eberhard; Serge Weis; Herbert Reitsamer; Barbara Kofler
Journal:  J Neurooncol       Date:  2013-06-13       Impact factor: 4.130

4.  Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats.

Authors:  Jinshuang Li; Hao Ding; Yong Li; Hao Zhou; Wanhong Wang; Yong Mei; Ronglin Zhang
Journal:  Amino Acids       Date:  2021-06-05       Impact factor: 3.520

5.  Intracerebroventricular Injection of Alarin Increased Glucose Uptake in Skeletal Muscle of Diabetic Rats.

Authors:  Zhenwen Zhang; Yongkang Wu; Shudong Sheng; Lili Guo; Biao He; Penghua Fang; Mingyi Shi; Ping Bo; Yan Zhu
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

6.  Thermoregulatory effect of alarin, a new member of the galanin peptide family.

Authors:  Alexandra Mikó; Péter Balla; Judit Tenk; Márta Balaskó; Szilvia Soós; Miklós Székely; Susanne Brunner; Barbara Kofler; Erika Pétervári
Journal:  Temperature (Austin)       Date:  2014-07-02

Review 7.  Neuropeptidergic Control of Feeding: Focus on the Galanin Family of Peptides.

Authors:  P Marcos; R Coveñas
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.